



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/403,056	10/13/1999	ROGER CAROLUS AUGUSTA EMBRECHTS	JAB-1267	6783

7590

01/15/2002

PHILIP S. JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

EXAMINER

KISHORE, GOLLAMUDI-S

ART UNIT

PAPER NUMBER

1615

DATE MAILED: 01/15/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
09/403,056

Applicant(s)
Embrechts

Examiner
Gollamudi S. Kishore, Ph.D

Art Unit
1615



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE three MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on Dec 3, 2001
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-19 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- *See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892)
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____
- 18) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 19) ☐ Notice of Informal Patent Application (PTO-152)
- 20) ☐ Other:

Art Unit: :1615

DETAILED ACTION

The filing under 1.53 (d) and the preliminary amendment dated 12-3-01 are acknowledged.

Claims included in the prosecution are 1-19.

Claim Rejections - 35 U.S.C. § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:**

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

- 2. Claims 1-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Liu (5,456,851), Mason (5,536,742) individually or in combination, further in combination with Fost (5,688,496), (5,648,348) and Vanmiddlesworth (5,164,375).**

Liu discloses shampoo formulations containing the various additives and ketonazole as the active ingredient; Liu also discloses that ketonazole is an anti-fungal agent and is

Art Unit: :1615

useful for the treatment of psoriasis and seborrheic dermatitis (note the abstract, columns 1-4, Examples and claims).

Mason similarly discloses shampoo preparations containing ketonazole, econazole or miconazole for the treatment of seborrhoea. Mason notes the association of this disease with yeast (fungus) (note the abstract, columns 1-2 and claims).

What is lacking in the above references is the inclusion of a phospholipid in the shampoo preparations.

Fost (496) while disclosing skin and hair care compositions including shampoos containing synthetic phospholipids teaches the excellent properties of phospholipids such as foaming, viscosity building, wetting, cleansing, detergency and conditioning which makes them very useful (note the abstract, col.1, line 18 through col. 2, line 25, col. 6, line 54 et seq., columns 15-17, examples 16-18 and claims).

Fost (348) while disclosing various personal care products teaches that the synthetic phospholipids have excellent antifungal activity (note the abstract, columns 6-7, examples and claims).

VanMiddlesworth teaches that a synthetic phospholipid of his invention has antifungal activity (note the abstract).

The inclusion of a phospholipid in the shampoo compositions of Liu or Mason would have been obvious to one of ordinary skill in the art since the secondary references

Art Unit: :1615

clearly teach the excellent properties of the phospholipids and also their anti-fungal activity.

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant once again argues that Lie, and Mason do not teach phospholipids; the examiner agrees, but points out that the secondary references the use of phospholipids. Applicant argues that the phospholipids in Fost 348 have a structure different from the phospholipids in Fost 496 and therefore, there is neither a disclosure nor a suggestion in Fost 348 to include its antifungal/antibacterial phospholipids. This argument is not found to be persuasive since instant claims do not recite that the phospholipid be anti-fungal/antibacterial phospholipid; the references of Fost clearly indicate the advantages of using phospholipids and indeed as recognized by applicant himself, one of the phospholipids taught by Fost has these properties and furthermore, the phospholipid taught by Vanmiddlesworth has these properties. With regard to the synergistic properties argued:- a close examination of the results on page 15 of the specification appear to indicate no controls with the antifungal agent or the phospholipids by themselves were performed and no statistical significance of the results has been presented. The examiner points out that scope of the claims is not commensurate with the synergistic effect observed in terms of generic 'antifungal' and phospholipid and in terms of organisms.

3. Claims 1-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Liu (5,456,851), Mason (5,536,742) individually or in combination, further in

Art Unit: :1615

combination with Fost (5,688,496), (5,648,348) and Vanmiddlesworth (5,164,375) as set forth above, further in view of GB 22 56 139.

The teachings of Liu, Mason, Fost and Vanmiddlesworth have been discussed above.

GB while disclosing emulsions containing terbinafine and phospholipids, teaches that such a combination results in enhanced efficacy of the compound (note the abstract, page 2, 4 and examples; example 3 in particular).

One of ordinary skill in the art would be motivated further to use phospholipids together with the antifungal compounds in view of the enhanced efficacy of antifungal agents taught by GB.

Art Unit: :1615

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *G.S. Kishore* whose telephone number is (703) 308-2440.

The examiner can normally be reached on Monday-Thursday from 6:30 A.M. to 4:00 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, T.K. Page, can be reached on (703)308-2927. The fax phone number for this Group is (703)305-3592.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [thurman.page@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Application/Control Number: 09/403,056

Page 7

Art Unit: :1615

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703)308-1235.



Gollamudi S. Kishore, Ph. D

Primary Examiner

Group 1600

gsk

January 14, 2002